|
Glezen, W Paul; Gaglani, Manjusha J; Kozinetz, Claudia A et al. (2010) Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 202:1626-33
|
|
Gaglani, Manjusha J; Piedra, Pedro A; Riggs, Mark et al. (2008) Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 27:444-52
|
|
Halloran, M Elizabeth; Piedra, Pedro A; Longini Jr, Ira M et al. (2007) Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 25:4038-45
|
|
Piedra, Pedro A; Gaglani, Manjusha J; Riggs, Mark et al. (2005) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116:e397-407
|
|
Piedra, Pedro A; Gaglani, Manjusha J; Kozinetz, Claudia A et al. (2005) Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23:1540-8
|
|
Gaglani, Manjusha J; Piedra, Pedro A; Herschler, Gayla B et al. (2004) Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158:65-73
|
|
Halloran, M Elizabeth; Longini Jr, Ira M; Gaglani, Manjusha J et al. (2003) Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158:305-11
|
|
Smith, Catherine B; Cox, Nancy J; Subbarao, Kanta et al. (2002) Molecular epidemiology of influenza A(H3N2) virus reinfections. J Infect Dis 185:980-5
|
